Group of Genetically Engineered Biopharmaceutical Technologies

NamePositionContacts
Roman Esipov, Ph.D.depart. dir.esipov@ibch.ru+7(495)336-68-33
Tat'jana Murav'eva, Ph.D.s. r. f.+7(495)3307247
Maria Kostrominaj. r. f.
Dmitry LykoshinPhD stud.
Evgeny Zayatsstud.
Mikhail Tereshinstud.
Renata Muhutdinovastud.
Tatyana Petrovastud.
Dmitriy Kravcovstud.
Elena Tuzovat. q. - lab. as.
Ol'ga Uznadzeeng.
Olga Mikheevaeng.olga.mikheeva.92@mail.ru
Larisa Esipovasen. eng.

Former members:

Vasiliy Stepanenko, Ph.D.s. r. f.svn@ibch.ru
Larisa Chupova, Ph.D.r. f.
Ekaterina Sinitsinastud.
Anna Potapovastud.
Artemiy Litunovstud.
Dmitry Makarov, Ph.D.k. eng.youngchemist@mail.ru

Selected publications (show all)

Loading...

Roman Esipov

  • Russia, Moscow, Ul. Miklukho-Maklaya 16/10 — On the map
  • IBCh RAS, build. 53, office. 5607
  • Phone: +7(495)336-68-33
  • E-mail: esipov@ibch.ru

Development of methods for obtaining thymosin beta 4 analogs as conjugates with extended half-life in vivo (2017-11-28)

A method for the production of monocojugates of recombinant human thymosin β4 (Тβ4) with capronic acid, polysialic acid 14 kDa and polyethylene glycol 10 kDa has been developed. As a result of multifactorial experiments, the components of the reaction mixtures were identified, and conditions of those reactions were optimized. For each analog, we developed a single-stage RP HPLC purification procedure that enabled to attain the purity of no less than 98%. The peptide mapping results backed up by chromatography-mass spectrometry and electrophoresis demonstrated that the produced Тβ4 analogs are monoconjugates in which the initial peptide is modified at the N-terminal serine residue. The produced analogs feature a higher resistance to degradation in the blood plasma as compared to non-modified Tβ4, and they can be regarded as promising candidates for further biological testing.